Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema.

Abstract

To report on a patient who developed a lamellar macular hole 1 month after an intravitreal pegaptanib sodium injection. Interventional case report. A 66 year old patient developed a lamellar macular hole 1 month after an intravitreal pegaptanib sodium injection for diabetic macular edema (DME). The pathogenesis of the lamellar macular hole in our case can be attributed to the intravitreal injection that may have induced vitreous incarceration, causing vitreoretinal traction at the macula and development of a lamellar macular hole. Alternatively or in association, pegaptanib itself may have caused the lamellar macular hole by inducing sudden reduction of the DME and exacerbation of tangential traction of the posterior vitreous on the overlying macular retina. Lamellar macular hole seems to be a potential complication of pegaptanib injection even in patients without pretreatment clinically detectable vitreomacular traction.

• Authors: Giuseppe Querques, Anna V Bux, Cristiana Iaculli, Nicola Delle Noci
• Journal: International ophthalmology (Int Ophthalmol) Vol. 31 Issue 6 Pg. 525-7 (Dec 2011) ISSN: 1573-2630 [Electronic] Netherlands
• PMID: 22203375 (Publication Type: Case Reports, Journal Article)

Chemical References

• Aptamers, Nucleotide
• Vascular Endothelial Growth Factor A
• pegaptanib

Topics

• Aged
• Aptamers, Nucleotide (adverse effects)
• Diabetic Retinopathy (drug therapy)
• Female
• Humans
• Intravitreal Injections
• Macular Edema (drug therapy)
• Retinal Perforations (chemically induced)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)